Welcome to our dedicated page for Inogen news (Ticker: INGN), a resource for investors and traders seeking the latest updates and insights on Inogen stock.
Inogen Inc (INGN) is a pioneering medical technology company specializing in portable oxygen concentrators for respiratory care. This dedicated news hub provides investors and healthcare professionals with essential updates on product developments, regulatory milestones, and strategic initiatives.
Access timely announcements including quarterly earnings reports, FDA clearances for new devices, partnership agreements with healthcare providers, and clinical study results. Our curated collection ensures you stay informed about innovations in oxygen therapy technology and market expansion efforts.
Key focus areas include advancements in lightweight oxygen systems, international distribution updates, and operational developments impacting respiratory patient care. Bookmark this page for direct access to primary source materials and analyzed updates from INGN's corporate communications.
Inogen (Nasdaq: INGN) has announced the appointment of Kevin P. Smith as General Counsel and Executive Vice President of Business Development, effective July 22, 2024. Smith brings nearly 30 years of experience in the medical technology and legal fields, having previously served at Sirtex Medical and Flexion Therapeutics. His extensive background in securities, business development, and intellectual property is expected to strengthen Inogen's legal and business strategy teams. CEO Kevin Smith emphasized the importance of Smith's role in maintaining the company's integrity and compliance.
Inogen, a medical technology company specializing in respiratory products, announced findings from a study published in Pulmonary Therapy. The research, sourced from France's national healthcare database (SNDS), analyzed over 244,000 long-term oxygen therapy patients from 2013-2020. Results demonstrated that portable oxygen concentrators (POCs), alone or combined with other oxygen modalities, improved survival rates and were cost-effective compared to stationary concentrators, compressed tanks, and liquid oxygen. Additionally, Inogen's higher mobility POC devices, with autonomy over 5 hours, showed better outcomes in survival, healthcare resource use, and related costs than lower mobility devices.
Inogen, Inc. (Nasdaq: INGN) announced their first quarter 2024 financial results, showing an 8.1% increase in total revenue to $78.0 million, accompanied by a total gross margin of 44.1%. The GAAP net loss was $14.6 million, with adjusted net loss at $10.4 million. Adjusted EBITDA was a negative $7.6 million. Inogen expects revenue for the second quarter of 2024 to be in the range of $81 million to $84 million. The company remains focused on revenue growth, profitability, and innovation to enhance their market position.
FAQ
What is the current stock price of Inogen (INGN)?
What is the market cap of Inogen (INGN)?
